Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: NVP ER 400 mg (KCR 25%) Medium Release
Drug: NVP ER 300 mg (KCR 40%) Slow Release
Drug: NVP ER 300 mg (ECR 20%) Fast Release
Drug: NVP ER 400 mg (KCR 20%) Medium Release
Drug: NVP ER 400 mg (KCR 30%) Slow Release
Drug: Nevirapine immediate release (IR) 200 mg
Drug: NVP ER 300 mg (KCR 25%) Medium Release
Drug: NVP ER 400 mg (ECR 20%) Fast Release
Drug: NVP ER 300 mg (KCR 20%) Medium Release
Drug: NVP ER 300 mg (KCR 30%) Slow Release
Drug: NVP ER 400 mg (KCR 40%) Slow Release

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 204

Registration Number: NCT02192463

Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency

Phase 2

Completed

Conditions: Venous Insufficiency

Interventions: Drug: Antistax®
Drug: Placebo

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 71

Registration Number: NCT02191163

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Linagliptin - Multiple dose
Drug: Linagliptin - single dose

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 51

Registration Number: NCT02191228

Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®

Completed

Conditions: HIV Infections

Interventions: Drug: Viramune® tablets

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 228

Registration Number: NCT02191293

Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dextromethorphan syrup - high dose
Drug: Dextromethorphan syrup - low dose
Drug: Placebo

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02191176

Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation

Completed

Conditions: Myocardial Infarction

Interventions: Drug: METALYSE®

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02191670

Micardis® in Patients With Essential Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan tablets

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1688

Registration Number: NCT02187705

Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Simvastatin
Drug: Telmisartan placebo

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02187536

Study to Assess the Kinetic of the Analgesic Effect and Tolerability of Eschscholtzia Californica Versus Ibuprofen and Placebo in the Treatment of Pain After Surgery of the Third Molar

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Eschscholtzia Californica - high dose Placebo
Drug: Eschscholtzia Californica - low dose
Drug: Eschscholtzia Californica - high dose
Drug: Ibuprofen
Drug: Ibuprofen Placebo
Drug: Eschscholtzia Californica - low dose Placebo

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT02187588

Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Hydrochlorothiazide
Drug: Telmisartan/HCTZ FDC
Drug: Telmisartan

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02187523

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy